Weight-loss drugs and binge eating disorder

Binge eating disorder (BED) sits in a confusing spot in the weight-loss-drug conversation. It is the most common eating disorder, it is more common at higher body weights, and there is genuine research interest in whether GLP-1 medications might reduce binges. That combination has led some people to assume weight-loss drugs are a treatment for BED. The reality is more careful, and getting it wrong can make things worse. This page lays out what the research actually shows, why a weight-loss focus can backfire, and where these medications do and do not fit. For the condition itself, see binge eating disorder.

What the research does and does not say

The research interest is real and worth describing accurately, in both directions. Because GLP-1 medications reduce appetite and the drive to eat, researchers have asked whether they could lower binge frequency, and some small, short studies have reported a signal in that direction.¹ That is genuinely interesting.

But a research signal is not a treatment recommendation. The studies so far are small and short, the medications are not FDA-approved for binge eating disorder, and the long-term effect on the disorder itself, as opposed to short-term binge counts or weight, is not settled.¹ A 2024 systematic review concluded that large-scale, blinded, placebo-controlled trials are still lacking and that rigorous clinical trials are needed before GLP-1 medications can be considered an established option for binge eating.¹ Treating BED as something a weight-loss drug simply fixes skips over what actually works, and risks swapping a real treatment for an unproven one.

Why a weight-loss focus can backfire

This is the crucial point, and it is where intuition often misleads. Binge eating disorder is frequently driven by restriction and weight-focused dieting: cycles of restricting set up the binges, and the distress about weight keeps the cycle turning.² A weight-loss-focused intervention can therefore reinforce the very pattern that fuels BED.

Treatment that reduces restriction and rebuilds regular, adequate eating tends to help, while an approach that increases the focus on eating less and weighing less can deepen the cycle. That is why "diet harder" or "turn to a weight-loss drug" is so often the wrong instinct for binge eating disorder, even though it feels like the obvious one.

What actually helps binge eating disorder

The psychological treatments with the strongest support for BED are cognitive behavioral therapy, interpersonal therapy, and dialectical behavior therapy; the National Institute of Mental Health describes cognitive behavioral therapy and interpersonal psychotherapy as established approaches for eating disorders.³ The one medication FDA-approved for moderate-to-severe binge eating disorder is lisdexamfetamine (Vyvanse). The U.S. Food and Drug Administration approved it for that use in 2015. It is used as part of a treatment plan for binge eating, not as a weight-loss tool.⁴

Where a GLP-1 might still come up

A person with binge eating disorder may also have a separate medical reason a GLP-1 is being considered, such as diabetes. That decision belongs with a clinician who knows the eating disorder history and can coordinate with the treatment team, the same coordinated approach we describe for GLP-1 drugs during eating disorder recovery. The order of operations matters: assessment and evidence-based treatment for the BED come first, and any weight medication is a separate, carefully monitored decision, not the BED treatment itself.

In short

If you have binge eating disorder, a weight-loss drug is not the place to start, and a weight-loss focus can make the cycle worse. Start with an assessment and evidence-based treatment. If a GLP-1 is being considered for a co-occurring medical reason, that decision belongs with a clinician who knows your eating disorder history. Read more on binge eating disorder or search for licensed programs.